scRNA-seq of PC9 EGFR-mutant NSCLC xenografts treated with osimertinib and/or trastuzumab deruxtecan
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Fields of Study & Subjects
Lung Cancer Treatments and Mutations
HER2/EGFR in Cancer Research
Cancer Genomics and Diagnostics
Publication details
- Publication date
- 30 March 2026
- Language
- EN
- Document type
- Dataset